Therapeutic Effects of Synthetic Antimicrobial Peptides, TRAIL and NRP1 Blocking Peptides in Psoriatic Keratinocytes

Sunhyo Ryu¹, Lindsey Broussard¹, Chakyung Youn², Brendon Song³, David Norris¹, Cheryl A. Armstrong¹, Beomjoon Kim⁴, and Peter I. Song¹, *

¹Department of Dermatology, University of Colorado Denver School of Medicine, Aurora, CO, USA, ²Department of Biomedical Science and Research Center for Proteanence Materials, Chosun University School of Medicine, Gwangju, Korea, ³Department of Biology, University of Denver, Denver, CO, USA, ⁴Department of Dermatology, Chung-Ang University School of Medicine, Seoul, Korea

Psoriasis is a chronic, recurrent, heterogeneous, cutaneous inflammatory skin disease for which there is no cure. It affects approximately 7.5 million people in the United States. Currently, several biologic agents that target different molecules implicated in the pathogenic processes of psoriasis are being assessed in diverse clinical studies. However, relapse usually occurs within weeks or months, meaning there is currently no cure for psoriasis. Therefore, recent studies have discovered diverse new potential treatments for psoriasis: inhibitors of bacteria such as Staphylococcus aureus, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and neuropilin 1 (NRP1).

A promising approach that has recently been described involves modifying antimicrobial peptides to develop new cutaneous anti-bacterial agents that target inflammatory skin disease induced by Staphylococcus. Increased expression of TRAIL and its death receptors DR4 and DR5 has been implicated in the pathogenesis of plaque psoriasis. In addition, TRAIL has the ability to inhibit angiogenesis by inducing endothelial cell death and by negative regulation of VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions. Since NRP1 regulates angiogenesis induced by multiple signals, including VEGF, ECM and semaphorins, and also initiates proliferation of keratinocytes through NF-κB signaling pathway in involved psoriatic skin, targeting NRP1 pathways may offer numerous windows for intervention in psoriasis. In this review, we will focus on the current knowledge about the emerging role of synthetic antimicrobial peptides, TRAIL and NRP1 blocking peptides in the pathogenesis and treatment of psoriasis.

Key Words: Psoriasis; Anti-Bacterial Agents; TNF-Related Apoptosis-Inducing Ligand; Neuropilin-1

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Psoriasis is a chronic, recurrent, inflammatory skin disease characterized by prominent epidermal hyperplasia and a distinct inflammatory infiltrate. The estimated prevalence of this cutaneous disease is between 0.5% and 3.15% of the U.S. population.¹доб. The disease pathogenesis results from the interplay between immunocytes and keratinocytes and the resulting production of cytokines, chemokines, and growth factors. Several different forms of psoriasis have been described such as inverse psoriasis, pustular psoriasis, guttate psoriasis, and psoriasis vulgaris.

Psoriatic arthritis is a distinct inflammatory arthritis seen in conjunction with psoriasis, but with varied timing and genetic control. Most psoriasis patients develop a chronic ‘plaque-type’ psoriasis referred to as psoriasis vulgaris through a primarily T helper (Th17)/cytotoxic T (Tc) 17-type immune profile.⁵,⁶ Although these cytokine profiles control the infiltrative T cells of psoriatic lesions and the epidermal response, the main factors responsible for pla-
que formation and disease severity are yet to be fully distinguished. As antigen-specific T-cell activation is considered crucial in the development of the disease, it is hypothesized that antigen presentation in the skin might be linked to the activation of specific T-cell subsets at the site. In psoriasis vulgaris, novel autoantigens, LL-37 and a disintegrin like and metalloprotease domain containing thrombospondin type 1 motif-like 5 (ADAMTS15), have recently been identified as stimuli in the Th17/Tc17 activation of psoriatic lesions.5-7

In early lesions of human psoriatic skin, the characteristic dermal changes include tortuous dilated blood vessels, papillary edema, and perivascular infiltration composed of dendritic cells (DCs), lymphocytes, and macrophages. In chronic lesions, such as those in patients with plaque psoriasis, the epidermal changes become more evident which include thickening (acanthosis), elongation of rete ridges, and finally elongation of the dermal papillae which contain dilated capillaries. Proliferation of keratinocytes predominates in both the basal and suprabasal layers of the epidermis. As such, disturbing the differentiation process of keratinocytes can ultimately reduce thickness of the stratum granulosum of the epidermis. This results in irregularly thickened stratum corneum (hyperkeratosis) and retention of the nuclei inside corneocytes (parakeratosis).8

Unlike other inflammatory skin diseases, infiltrating inflammatory cells in the dermis of psoriatic lesions include macrophages, neutrophils, and lymphocytes. In these lesions, CD4+ T cells represent the majority of lymphocytes localized to the dermis, while CD8+ T cells reside primarily within the epidermis.8-10 In pustular variants especially, neutrophil infiltration within the stratum corneum and adjacent epidermal layers is a diagnostic histopathological feature.8

Psoriasis is a uniquely human condition, but numerous genetic approaches to model the disease in mice have been attempted. Most of the mouse models of psoriasis-like disease show the histopathological features that closely resemble those observed in human psoriasis, though the pattern and type of immune cell infiltrate has yet to be exactly reproduced. Current mouse models only capture psoriasis-like skin disease with plaque-like lesions that have features such as hyperkeratosis and/or parakeratosis, infiltration of T cells within the epidermis, neutrophilic microabscesses, enhanced vascularization, and finally involvement of joints and nails similar to psoriatic arthritis.8-10

Despite therapeutic advances, complete remission in psoriasis patients is not achievable, and relapse often occurs within weeks or months. In this review, we describe the current knowledge about the emerging role of synthetic antimicrobial peptides (AMPs), TRAIL and NRP1 blocking peptides in the pathogenesis of psoriasis and the potential for identifying new drug targets with better efficacy and less adverse effects.

CURRENT TREATMENTS

A multitude of topical and systemic treatments, including corticosteroids, vitamin D3 analogs, retinoids, methotrexate and cyclosporin, in addition to phototherapy with ultraviolet irradiation have been successfully used for the treatment of psoriasis. In the past decade, the development of biologic agents has shown promising therapeutic benefit for refractory cases of psoriasis. These biologic agent target either general inflammation through the TNF pathway, or specific immune cell activation through manipulation of CD2, IL-12, IL-17 and IL-23 expression.11,12 These systemic agents that have been developed and approved to treat moderate-to-severe psoriasis include T-cell inhibitors (efalizumab and alefacept),13,14 tumor necrosis factor (TNF-α) inhibitors (infliximab, adalimumab, and etanercept),15-17 interleukin (IL)-12/17 inhibitors (secukinumab, ixekizumab, ustekinumab, and brodalumab),18-25 and small molecule inhibitors such as the janus kinase inhibitor, tofacitinib, and the phosphodiesterase 4 inhibitor, apremilast.26,27

Unfortunately, these drugs have potentially serious side effects and can predispose patients to the development of both infectious disease and malignancy due to immune modulation and suppression. Even with these strong therapeutic agents, relapse often occurs in patients. Therefore, it is increasingly important to identify new therapies with better efficacy and less adverse effects. Owing to the heterogeneity of psoriasis, future treatments are unlikely to be restricted to individual biological targets. Instead, it will be advantageous to focus on concurrent use of therapies to fight immune over activation and to repair differentiation mechanisms of epidermal keratinocytes at various stages of disease. It will also be advantageous to identify new drugs that can be used to wean patients off carcinogenic-immunosuppressive effects that were first used to obtain clinical responses.

PATHOGENESIS OF PSORIASIS

Although the cause of psoriasis is not fully understood, there are two main hypotheses regarding the etiology of disease development. The first considers psoriasis as primarily a disease of epidermal keratinocytes, in which disordered inflammation is also necessary for disease development. The second hypothesis is that the disease is an immune-mediated disorder in which the production of cytokines such as tumor necrosis factor-alpha TNFα, chemokines and growth factors by immunocytes and keratinocytes results in inflammation and epidermal hyper-proliferation. Once activated, T cells migrate toward the dermis and stimulate cytokine release which induces rapid production of skin cells. IL-17A and other cytokines act on keratinocytes to propel further inflammatory mediator production, thereby creating an inflammatory loop.

Skin homeostasis is regulated by communicating skin cell types as well as factors such as cytokines, chemokines
and growth factors. This homeostasis can be interrupted by genetic alterations in the key signaling pathways of the immune system, provoking inflammation and psoriasis. Current mouse models have focused on keratinocytes, immune cells, and especially T cells as disease initiators in the disease process. Psoriasis, previously considered a uniquely T-cell-dependent disease, is now thought to be more complex with keratinocytes playing a fundamental role in eliciting the initial pathogenic events and then sustaining the chronic phase of the disease. Early in psoriasis, keratinocytes induce innate immunity and represent the “first-line responding” skin cells in the microenvironment. As shown in Fig. 1, keratinocytes mediate innate immunity though triggering pathways, such as skin trauma, pathogens (i.e., S. aureus), or drugs (Fig. 1). In psoriasis, stressed keratinocytes produce LL-37, which stimulates plasmacytoid DCs (pDCs) to produce IL-23, TNF, and interferon (IFN)-α. Keratinocytes also produce IL-1β, IFN-γ and TNF when under stress or dying, which activates DC to produce the proinflammatory cytokines and vascular endothelial growth factor (VEGF), ultimately resulting in vascular permeability and leukocyte adhesion to microvascular endothelium. Activated DCs migrate into the skin-draining lymph node and promote differentiation of the naïve CD4+ and CD8+ T cells into IL-12-induced Th1 cells and IL-23-induced Th17 cells, respectively. Inflammatory cells, which are attracted by these keratinocyte-derived factors, migrate into the skin via lymphatic and blood vessels. Th1 cells interact with DCs on the dermis, which secrete cytokines such as IL-23 and TNF. These products then stimulate keratinocytes to activate NKT cells via the production of TNF and IFN-γ. In the dermis, Th17 cells secrete IL-17AF, IL-21, IL-22, TNF and IFN-γ. The release of these cytokines prompts the production of IL-1β, IL-6 and other keratinocyte-derived cytokines and chemokines, which subsequently stimulate keratinocyte proliferation and impair keratinocyte differentiation. In addition, Th1- and Th17-derived cytokines induce the release of β-defensins, the neutrophil chemoattractant and antimicrobial S100 proteins, and the neutrophil-recruit-

![FIG. 1. The pathogenesis of psoriasis. Aberrant interplay of keratinocytes and immune cells in psoriasis. Cytokines produced by immune cells act on keratinocytes to activate further inflammatory mediator such as cytokines, chemokines, VEGF and AMPs, which creates an inflammatory loop.](image-url)
flammary response in genetically susceptible keratinocytes. The stimulated keratinocytes are capable of initiating an immune response through the production of various proinflammatory cytokines, which feedback on the keratinocytes, inducing further production of cytokines. Several antigens produced by stimulated keratinocytes, such as LL37 cathelicidin/nucleic acid complexes, newly generated lipid antigens, have been identified, and are suspected of inducing the initial activation of T cells. In turn, these Th1, Th17, and Th22 immune cells contribute to the development of psoriasis by secreting various cytokines including interferon-γ (IFN-γ), tumor necrosis factor α (TNF-α), and interleukin 17 (IL-17). Thus, keratinocyte activation directly or indirectly contributes to the major histological features of psoriasis as discussed above. Although the identities of the specific cells that trigger the pathogenesis of psoriasis are unknown, mouse models have elucidated the roles of keratinocytes and T cells as disease initiators. Furthermore, it has been found that skin homeostasis can be interrupted by inflammatory cells due to genetic aberrations or abnormalities that affect key signaling pathways involved in inflammatory immune responses in keratinocytes, resulting in psoriasis. Thus, despite the current focus on the role of T cells, the keratinocytes affected by psoriasis are also clearly abnormal in many respects and likely overstimulate immunocytes via positive feedback of inflammatory cytokines and chemokines. One other notable abnormality in psoriatic keratinocytes is the overproduction of AMPs.

INTRODUCTIONS OF MATERIALS FOR THERAPEUTICS OF PSORIASIS: SYNTHETIC AMPs, TRAIL AND NR1 BLOCKING PEPTIDES

1. Synthetic antimicrobial peptides (AMPs)

Although psoriasis is classified as an autoimmune disease, considerable evidence suggests an important role for bacteria such as Staphylococcus aureus (S. aureus) in the pathogenesis of psoriasis. Several mutations in more than one gene have been implicated, and evidence suggests that environmental factors such as a common viral or bacterial infection or simple injury contribute to their activation and expression. Skin infections with S. aureus are thought to serve as initiation and/or persistence factors for numerous inflammatory skin diseases, including psoriasis. Colonization and/or infection with Staphylococcus and Streptococcus have been reported to exacerbate psoriasis and many other inflammatory skin conditions. It has been theorized that toll-like receptors (TLRs) mediate this response through recognition of exogenous, microbial products and subsequent elicitation of a robust immune response. For example, VEGF-transgenic mice develop psoriasiform plaques that resemble human psoriasis. Peptidoglycan (PGN) from S. aureus induces expression of VEGF and subsequently IL-13 in keratinocytes, and IL-13 further induces VEGF expression via positive feedback. PGN induced VEGF and IL-13 expression was blocked by anti-Toll-like receptor 2 (anti-TLR2) antibody. These results suggest that PGN from S. aureus can further stimulate LL37 and VEGF expression in keratinocytes through TLR2, and that this VEGF production can be amplified by ensuing IL-13 overproduction. This implies that PGN from S. aureus is involved in the development of psoriasis via induction of VEGF expression.

S. aureus has multiple mechanisms to modulate the immune system; one is through the production of proteins such as superantigen toxins, Staph protein A, and the cytolytic Staph α-toxin. Ezepchuk et al. found that S. aureus isolates from the skin of patients with atopic dermatitis and psoriasis were either characteristic superantigenic toxins or thermodurable toxins, secreting α-toxin and extracellular staphylococcal protein A. When superantigen-stimulated immunocytes were injected into normal skin from subjects with psoriasis xenografted onto an immunodeficient mouse, clinical, histologic, and immunologic changes consistent with psoriasis were established. Staphylococcal protein A, α-toxin, and superantigen toxins derived from S. aureus, which was isolated from patients with psoriasis and atopic dermatitis, can directly induce pro-inflammatory responses in keratinocytes through the release of TNF-α (Fig. 2). Superantigen (SAg), as an enterotoxin, activates keratinocytes through MHC-II molecules, resulting in the production of TNF-α as well as a calcium mobilization response. In contrast, S. aureus-derived protein A does not appear to activate a calcium mobilization response although it is a potent inducer of TNF-α production through an unknown mechanism in keratinocytes. In addition, α-toxin triggers a calcium mobilization response as well as TNF-α production through the formation of a heptameric transmembrane pore.

The currently available biologic agents for treatment of psoriasis have serious side effects as a result of immunomodulation. Therefore, many researchers have tried to develop new therapeutic agents for psoriasis that have a higher therapeutic activity, but fewer side effects. AMPs are a class of peptides synthesized by every type of living organism to quickly eliminate Gram-positive and negative bacteria, fungi, parasites, enveloped viruses, and tumor cells, and are promising as future therapeutic agents. Natural AMPs are involved in host defense mechanisms in a variety of organisms such as cecropins in insects, Magainin in frogs, and defensins in rabbit, guinea pig, rat, and human neutrophils. AMP molecules are short (10-50 amino acids), with an overall positive charge and have both potent antimicrobial activity and anti-inflammatory effects. Recently, manipulation of natural peptides and synthetic peptides through modification of amino acids led to the development of a novel class of antimicrobial agents, which could be an alternative to the use of conventional antibiotics. As shown in Fig. 2, a direct interaction of S. aureus with keratinocytes or psoriatic keratinocytes plays a critical role in inflammation. Several reports have suggested that S. aureus promotes inflammation by stimulating keratinocytes to produce a number of proinflammatory cyto-
S. aureus

FIG. 2. Schematic diagram of a synthetic antimicrobial peptides on antimicrobial and anti-inflammatory activity in psoriatic keratinocytes. The antimicrobial and anti-inflammatory activity of the synthetic antimicrobial peptides (AMPs) may be attributed to: (I) a direct antimicrobial activity against S. aureus, (II) the ability of synthetic AMPs to bind bacterial factors such as peptidoglycan (PGN), lipoteichoic acid (LTA), protein A, α-Toxin, and superantigens (SAg), (III) the inhibitory activity of synthetic AMPs on the keratinocytes secretion of proinflammatory cytokines, chemokines, endogenous AMPs and VEGF.

Antimicrobial peptides and proteins act as moderators to link innate and adaptive immune mechanisms. Excessive production of AMPs induced by S. aureus is thought to modify the host inflammatory responses by a variety of mechanisms. They function as chemotactic agents, angiogenic factors, and regulators of cell proliferation. Recent advances highlight the role of the AMPs’ cathelicidin, S100 proteins, and defensins in disease susceptibility and manifestation of psoriasis. These AMPs play a significant role in interactions between resident keratinocytes and skin infiltrating immune cells. Skin injury and infections such as S. aureus trigger rapid expression of human cathelicidin, hCAP18, in keratinocytes or infiltrated neutrophils. LL37 binds to extracellular self-DNA fragments, allowing them inside plasmacytoid dendritic cells (pDCs) to express type I interferons (IFNα and β) via TLR9 activation. As a consequence, the type I IFNs activate Th1 or Th17 cells through myeloid dendritic cells, which leads to the expression of INF-γ, IL-22 and IL-17. IL-22 and IL-17 expression leads to more production and secretion of LL37, resulting in the pro-inflammatory feedback loop seen in psoriasis. AMPs are overexpressed in psoriatic lesions and function as alarmins on keratinocytes and other immune cells leading to heightened production of proinflammatory mediators and chemoattractant molecules for leukocytes. Thus, the normalization of aberrant, up-regulated expression of AMPs which is induced by S. aureus in keratinocytes and the inhibition of the early steps of inflammatory cascade in psoriasis might provide a therapeutic target in psoriasis. One problem in inhibiting AMPs is significant immunosuppression therefore this effect must be further investigated. While upregulation of AMPs worsen some aspects of psoriatic lesions, recent evidence has also suggested the possibility that the induction of AMP expression might improve certain aspects of psoriasis. Dombrowski et al. have discovered the anti-inflammatory effects of LL-37, which can block the activation of the DNA-sensing inflammasomes. This might be a mechanistic explanation regarding the effectiveness of vitamin D3 in psoriasis. It was discovered that intracellular or cytosolic LL-37 inhibits IL-1β release by blocking AIM2 inflammasomes in keratinocytes. Evidently, regulation of AMP expression and processing has an important role in psoriasis, but much remains to be learned about how they function.

2. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in psoriasis

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) family, which has potent cytotoxicity to tumor cells and transformed cells. TRAIL is a type II membrane protein that has an initial size of 33-35 kD, but can be cleaved from the cell surface by the aspartic proteinase cathepsin E to produce a soluble ligand of about 21 kD that retains biological activity. Once membrane bound, the extra-cellular domain of TRAIL assembles into a bell-shaped homo-trimer and three molecules of TRAIL fuse with three molecules of the transmembrane receptor as a hexameric complex (3:3).
TRAIL binds to five distinct receptors found on a multitude of cell types; four of these receptors are membrane-bound and one a soluble receptor. Two of these membrane receptors, TRAIL-R1/death receptor 4 (DR4) and TRAIL-R2/death receptor 5 (DR5), function agonistically, and each incorporate a cytoplasmic death domain by which TRAIL propagates an apoptotic signal. On the contrast, the other two membrane receptors, TRAIL-R3/decoy receptor 1 (DcR1) and TRAIL-R4/decoy receptor 2 (DcR2), have affinity to bind TRAIL, but function as antagonistic/regulatory receptors without a death domain. Along with these four transmembrane receptors, an additional soluble, antagonistic receptor, osteoprotegerin (OPG), has been recognized (Fig. 3). TRAIL serves as a crucial regulator of immune responses during infections and autoimmune disorders. Its role has been investigated in skin cancers, various inflammatory diseases, and autoimmune-mediated pathologies. TRAIL has the dual ability of inhibiting angiogenesis by triggering endothelial cell death or enhancing pro-angiogenic activity in vitro.\(^6^1\)

TRAIL has a strong ability to induce apoptosis in a concentration dependent manner. In fact, low concentrations of TRAIL can stimulate non-apoptotic action by promoting cell proliferation. Activated immune cells such as natural killer (NK) cells, T cells, macrophages and dendritic cells express membrane-bound TRAIL. On the contrast, soluble TRAIL is found in the sera of both normal individuals those affected by neoplastic disorders. Soluble TRAIL has also been detected in the culture supernatant of activated peripheral blood mononuclear cells (PBMC) when exposed to interferon. Therefore, it is thought to mediate antitumor cytotoxicity and function as an immune effector molecule. Interestingly, a significant level of TRAIL transcript has been discovered in many human tissues such as the colon, ovary, PBMC, placenta, prostate, spleen, small intestine, and thymus. In addition, TRAIL has constitutive expression in some tissues. In order to best characterize the biological activity of both full-length membrane and soluble TRAIL, Multiple experimental in vitro and in vivo models of the induction of apoptosis in neoplastic cells by TRAIL have been developed. Several studies have demonstrated that the TRAIL-TRAIL receptors system play a physiological role in normal angiogenesis through promotion of endothelial cell survival, migration, and proliferation. An anti-inflammatory activity of TRAIL has also been demonstrated by observing how TRAIL responds to inflammatory cytokines by counteracting the adhesion of both peripheral blood derived monocytes and granulocytes to endothelial cells in vivo without activating apoptosis.\(^6^1\)

TRAIL has been hypothesized to play a role in the pathogenesis of psoriasis. Caldarola et al.\(^6^2\) investigated the expression and localization of TRAIL, its receptors, and the intracellular pathways involved with TRAIL to elucidate any involvement in psoriasis pathogenesis. They reported increased production of TRAIL and its receptors in both lesional vs. non-lesional skin using RT-PCR. Also, TRAIL and TRAIL receptors were found in the epidermis and in the dermal infiltrate by immunohistochemistry. Finally, they found that caspase 8 and TRAIL expression in the dermis were correlated, hypothesizing that caspase 8 action at the site of the inflammation may explain these phenomena.\(^6^2\)

In psoriatic lesions, IFN-\(\gamma\) was observed to stimulate IL-23 and IL-1 production by DCs which ultimately activated Th17 cells in the inflammatory cascade. IFN-\(\gamma\) was intradermally injected once to a clinically normal and non-lesional area of skin in psoriasis patients and biopsies were collected after 24 hours. Although no visible changes were observed in the skin, areas injected with IFN-\(\gamma\) revealed many molecular and histological features typical of psoriatic lesions. IFN-\(\gamma\) also upregulated a number of differentially expressed genes in the skin as well as chemokines responsible for an influx of T cells and inflammatory myeloid DCs. Furthermore, the IFN-\(\gamma\)-treated skin contained inflammatory DC products tumor necrosis factor (TNF), inducible nitric oxide synthase, IL-23, and TRAIL, which further supports involvement of TRAIL in psoriasis pathogenesis.\(^6^3\)

The expression of TRAIL and its receptors DR4 and DR5 has been investigated in psoriasis vulgaris through immunohistochemistry staining. Notably, TRAIL stains were significantly pronounced in both psoriatic lesional and non-lesional epidermis when paralleled with the epidermis of healthy skin. There was also increased immunor-
eactivity for DR5 in lesional epidermis. Additionally, expression of TRAIL and both of its receptors was considerably amplified in the dermis of lesional skin. Cells of the inflammatory infiltrate in psoriatic lesions abundantly expressed TRAIL. The expression of DR4 was found localized in the nucleus of CD4+ and CD8+ cells, while in contrast, DR5 demonstrated mostly cytoplasmic staining in rare CD16+, CD56+ and CD68+ cells. Considering the abundant in situ presence of TRAIL and its receptors found in lesional psoriatic skin, there appears to be a complex relationship between keratinocytes and cells of the dermal infiltrate in psoriasis vulgaris.64

Zaba et al.65 previously reported that CD11c(+)CD1c(-) inflammatory dermal dendritic cells (DCs) in psoriatic lesional skin secrete a wide variety of inflammatory molecules compared with skin-resident CD11c(+) DCs. The differential expression of TRAIL, TLR1, TLR2, S100A12/ENRAGE, and CD32 were shown in inflammatory DCs compared to resident DCs. Keratinocytes treated with TRAIL expressed TRAIL receptors, death receptor 4, and decoy receptor 2; in contrast, dermal cells during in vitro culture of keratinocytes with TRAIL induced CCL20 chemokines. Considering these results, molecular products made by inflammatory DCs, including TRAIL as discussed above, have the potential to modulate keratinocytes or other skin cell types in psoriasis pathogenesis.65,66

It has recently been reported that TRAIL inhibits VEGF-induced angiogenesis of human umbilical vein endothelial cells (HUVECs) by increasing caspase-8 activity. TRAIL also decreases procaspase-8 associated non-apoptotic signaling functions without inducing caspase-3 activation and endothelial cell cytotoxicity. Since VEGF is an important factor in the development of psoriasis and psoriasiform like plaques in VEGF-transgenic mice, caspase-8 is a prom-
basal and supra basal layers of the skin epidermis. It is also expressed in fibroblasts, endothelial cells, and inflammatory cells of the dermis. However, the most intensive expression of NRP1 was observed in psoriatic skin. Highly elevated expression of NRP1 mRNA was detected in the epidermis and the dermis of psoriatic skin when compared with healthy skin. In addition, NRP1 expression is closely correlated with the expression of Ki67, a well-established proliferation marker. Moreover, it was reported that the signaling pathway of NK-κB is one that is putatively downstream of NRP1-associated signaling in HaCaT cells. This study suggests that NRP1 involvement in regulation of proliferation is through activation of the NF-κB pathway in keratinocytes in psoriatic skin. Furthermore, the expression of angiogenesis markers including soluble 12 NRP-1, VEGFR3 and VEGF-A isoform VEGF121 was highly increased in the non-lesional psoriatic skin as compared with that of normal healthy skin. Saban et al. reported that NRPs and VEGFRs play a role in migration of inflammatory cells and inflammation-induced lymph-angiogenesis. In this study, neutralizing antibodies against NRPs blocked the binding of VEGF to NRP (e.g. anti-NRP1 (B)) and the binding of semaphorins to NRP (anti-NRP1 (A)) in the BCG challenged C57BL/6 mice. They indicated that NRP1-neutralizing antibodies dramatically reduced scVEGF/Cy5.5 uptake as well as polymorphonuclear (myeloperoxidase+cells) and dendritic cell (CD11c+positive cells) infiltration in the NRP1-treated mice. The NRP1 treatment also decreased the overall density of BCG-induced blood and lymphatic vessels, indicating that NRPs play a critical role as in vivo regulators of the vascular and inflammatory responses in the BCG challenged C57BL/6 mice. Since vascular alterations are a significant hallmark in the pathogenesis of psoriasis, angiogenesis is a central process in the evolution of psoriasis. As such, anti-angiogenic treatments of psoriasis remain under evaluation for effectiveness. Therefore, targeting NRP1 interaction with VEGF/VEGFR, semaphorins may be a significant approach for intervention in psoriasis progression.

CONCLUSION

Although there are numerous effective treatments for psoriasis that target specific points in the pathogenic pathways that control psoriasis, there is no cure for psoriasis currently. To date, the pathogenic processes that control inflammatory skin disease are clinically characterized by prominent epidermal hyperplasia and a distinctive inflammatory infiltrate. Although psoriasis cannot be considered uniquely as a T-cell-dependent disease, the initiation, progression, and persistence of psoriasis is influenced by inflammation and immune circuits generated by the cross talk between autoreactive T cells and resident keratinocytes in psoriatic skin. As shown in Fig. 1, the disease chronicity in psoriasis may be determined by aberrant interplay of immune cells and cutaneous keratinocytes in intensified inflammation and autoimmune responses. Since keratinocytes also play a critical role in innate and adaptive immune responses, keratinocyte activation is characterized by the over-proliferation and overexpression of immunological molecules that are critical mediators in the development of psoriasis.

Angiogenesis is another central process in the development of psoriasis. For this reason, potential intervention on angiogenesis and keratinocyte activation represents an attractive therapeutic target against psoriasis. In this review, we focused on current knowledge about the emerging role of synthetic AMPs, TRAIL and NRP1 blocking peptides on angiogenesis and keratinocyte activation for the
pathogenesis and treatment of psoriasis. Considerable evidence suggests an important role for bacteria such as *S. aureus*, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and neuropilin 1 (NRP1) in the pathogenesis of psoriasis. Although psoriasis is classified as an autoimmune disease, it is now well accepted that colonization and/or infection with the bacteria such as *Staphylococcus* and *Streptococcus* in the skin have an important role in the pathogenesis of this condition. A promising approach for developing new cutaneous, anti-bacterial agents may lie with antimicrobial peptides because of their ability to efficiently kill microbial pathogens in addition to their anti-inflammatory effects. In this review, we have discussed TRAIL and its receptors DR4 and DR5, which are strongly expressed in plaque psoriasis. In addition, TRAIL has the ability to inhibit angiogenesis by inducing endothelial cell death and negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions. We also emphasized NRP1 as a coreceptor for VEGF and its role in regulating angiogenesis through signaling pathways associated with VEGF, ECM, and semaphorins. Given this background, novel modifications of synthetic AMPs, TRAIL, and NRP1-signaling in epidermal keratinocytes and angiogenesis are a potential target for psoriasis therapies. Further studies are clearly needed to define the specific mechanisms by which these molecules regulate angiogenesis and keratinocyte activation in order to better understand the pathogenesis and treatment of psoriasis.

**CONFLICT OF INTEREST STATEMENT**

None declared.

**REFERENCES**

1. Shbeeb M, Uramoto KM, Gibson LE, O’Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27:1247-50.
2. Boehncke WH, Schön MP. Psoriasis. Lancet 2015;386:983-94.
3. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46:850-60.
4. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009;60:218-24.
5. Arakawa A, Siewert K, Stöhr J, Besgen P, Kim SM, Rühl G, et al. Corrigendum: the antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 2015;6:6595.
6. Lebwohl M, Tyrring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13.
7. Ono S, Honda T, Doi H, Kabashima K. Concurrence of psoriasis vulgaris and atopic eczema in a single patient exhibiting different expression patterns of psoriatic autoantigens in the lesional skin. JAAD Case Rep 2018;4:429-33.
8. Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tschachler E. Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol 2010;6:704-14.
9. Conrad C, Nestle FO. Animal models of psoriasis and psoriatic arthritis: an update. Curr Rheumatol Rep 2006;8:342-7.
10. Gudjonsson JE, Johnston A, Dyson M, Valdimarsson H, Elder JT. Mouse models of psoriasis. J Invest Dermatol 2007;127:1292-308.
11. Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 2009;84(4 Suppl):14-24.
12. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50.
13. Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk 8. Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tschachler E. Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol 2010;6:704-14.
R, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012;167:668-77.

28. Blanpain C, Fuchs E. Epidermal homeostasis: a balancing act of stem cells in the skin. Nat Rev Mol Cell Biol 2009;10:207-17.

29. Albanesi C, De Pità O, Girolomoni G. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol 2007;25:581-8.

30. Albanesi C, Pastore S. Pathobiology of chronic inflammatory skin diseases: interplay between keratinocytes and immune cells as a target for anti-inflammatory drugs. Curr Drug Metab 2010;11:210-27.

31. Büchau AS, Gallo RL. Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol 2007;25:616-24.

32. Johnson-Huang LM, McNutt NS, Krueger JG, Lowes MA. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol 2009;29:247-56.

33. Zaba LC, Krueger JG, Lowes MA. Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol 2009;129:302-8.

34. Ghoreschi K, Weigert C, Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007;25:574-80.

35. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129:1339-50.

36. Conrad C, Boyman O, Tonel G, Tun-Kyi A, Laggner U, de Fougerolles A, et al. Alpha beta 1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 2007;13:836-42.

37. Plant D, Young HS, Watson RE, Worthington J, Griffiths CE. The CX3CL1-CX3CR1 system and psoriasis. Exp Dermatol 2006;15:900-3.

38. Sabat R, Philipp S, Höflich C, Kreutzer S, Wallace E, Asadullah K, et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007;16:779-98.

39. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol 2009;9:679-91.

40. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol 2012;7:385-422.

41. Albanesi C, Madonna S, Gisondi P, Girolomoni G. The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. Front Immunol 2018;9:1549.

42. Morizane S, Gallo RL. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol 2012;39:225-30.

43. Leung DY, Hauk P, Strickland I, Travers JB, Norris DA. The role of superantigens in human diseases: therapeutic implications for the treatment of skin diseases. Br J Dermatol 1998;139 Suppl 53:17-29.

44. Henderson CA, Hight AS. Acute psoriasis associated with Lancefield Group C and Group G cutaneous streptococcal infections. Br J Dermatol 1988;118:559-61.

45. Leung DY, Walsh P, Giorno R, Norris DA. A potential role for superantigens in the pathogenesis of psoriasis. J Invest Dermatol 1993;100:225-8.

46. Ruíz-González V, Cancino-Díaz JC, Rodríguez-Martínez S, Cancino-Díaz ME. Keratinocytes treated with peptidoglycan from Staphylococcus aureus produce vascular endothelial growth factor, and its expression is amplified by the subsequent production of interleukin-13. Int J Dermatol 2009;48:846-54.

47. Ezepchuk YV, Leung DY, Middleton MH, Bina P, Reiser R, Norris DA. Staphylococcal toxins and protein A differentially induce cytotoxicity and release of tumor necrosis factor-alpha from human keratinocytes. J Invest Dermatol 1996;107:603-9.

48. Boehncke WH, Dressel D, Zollner TM, Kaufmann R. Pulling the trigger on psoriasis. Nature 1996;379:777.

49. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996;98:1878-87.

50. Tossi A. Host defense peptides: roles and applications. Curr Protein Pept Sci 2005;6:1-3.

51. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002;415:389-95.

52. Koczulla AR, Bals R. Antimicrobial peptides: current status and therapeutic potential. Drugs 2003;63:389-406.

53. McPhee JB, Hancock RE. Function and therapeutic potential of host defence peptides. J Pept Sci 2005;11:677-87.

54. Boman HG, Hultmark D. Cell-free immunity in insects. Annu Rev Microbiol 1987;41:103-26.

55. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci U S A 1987;84:5449-53.

56. Lehrer RI, Ganz T, Selsted ME. Defensins: endogenous antibiotic peptides of animal cells. Cell 1991;64:229-30.

57. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009;30:131-41.

58. Ma HL, Liang S, Li J, Napierrona L, Brown T, Bonoït S, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008;118:597-607.

59. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2009;10:597-607.

60. Dombrowski Y, Peric M, Koglin S, Kammerbauer C, Göss C, Anz C, et al. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med 2011;3:82ra38.

61. Secchiero P, Zauli G. Tumor-necrosis-factor-related apoptosis-inducing ligand and its regulation in hematopoiesis. Curr Opin Hematol 2008;15:42-8.

62. Calderola G, Carbone A, Arena V, Pennacchia I, De Waure C, Vianale G, et al. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL): a possible pathogenic role in chronic plaque psoriasis. G Ital Dermatol Venereol 2016;151:17-24.

63. Johnson-Huang LM, Suárez-Fariñas M, Piirson KC, Fuentes-Duculan J, Cuoio L, Lentiini T, et al. A single intradermal injection of INF-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin. J Invest Dermatol 2012;132:1177-87.

64. Petrémel S, Prpić-Massari L, Manestar-Blažić T, Brajac I, Kaštelen L. Increased expression of TRAIL and its death receptors DR4 and DR5 in plaque psoriasis. Arch Dermatol Res 2011;303:389-97.

65. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Johnson-Huang LM, Nograles KE, White TR, et al. Identification of TNF-related
apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol 2010;125:1261-8.e9.

66. Na HJ, Hwang JY, Lee KS, Choi YK, Choe J, Kim JY, et al. TRAIL negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions. Angiogenesis 2014;17:179-94.

67. Saito N, Honma M, Shibuya T, Iinuma S, Igawa S, Kishibe M, et al. RIPK1 downregulation in keratinocyte enhances TRAIL signaling in psoriasis. J Dermatol Sci 2018;91:79-86.

68. Dannappel M, Vlantis K, Kumari S, Polykratis A, Kim C, Wachsmuth L, et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 2014;513:90-4.

69. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009;182:5836-45.

70. Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999;126:4895-902.

71. Lampropoulou A, Ruhrberg C. Neur opilin regulation of angiogenesis. Biochem Soc Trans 2014;42:1623-8.

72. Schwarz Q, Ruhrberg C. Neuropilin, you gotta let me know: should I stay or should I go? Cell Adh Migr 2010;4:61-6.

73. Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S, et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. Proc Natl Acad Sci U S A 2000;97:2573-8.

74. Gu C, Rodriguez ER, Reimert DV, Shu T, Fritzsch B, Richards LJ, et al. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev Cell 2003;5:45-57.

75. Nakamura F, Kalb RG, Strittmatter SM. Molecular basis of semaphorin-mediated axon guidance. J Neurobiol 2000;44:219-29.

76. Rossignol M, Gagnon ML, Klagsbrun M. Genomic organization of human neuropilin-1 and neuropilin-2 genes: identification and distribution of splice variants and soluble isoforms. Genomics 2000;70:211-22.

77. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 1997;90:739-51.

78. Kolodkin AL, Ginty DD. Steering clear of semaphorins: neurophins sound the retreat. Neuron 1997;19:1159-62.

79. Soker S, Fidder H, Neufeld G, Klagsbrun M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 1996;271:5761-7.

80. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-45.

81. Chen H, Chédotal A, He Z, Goodman CS, Tessier-Lavigne M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron 1997;19:547-59.

82. Giger RJ, Urquhart ER, Gillespie SK, Levengood DV, Ginty DD, Kolodkin AL. Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity. Neuron 1998;21:1079-92.

83. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J Biol Chem 2000;275:18040-5.

84. Gu C, Limberg BJ, Whitaker GB, Perman B, Leahy DJ, Rosenbaum JS, et al. Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J Biol Chem 2002;277:18069-76.

85. Parker MW, Hellman LM, Xu P, Fried MG, Vander Kooi CW. Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin. Biochemistry 2010;49:4068-75.

86. Henno A, Blacher S, Lambert C, Colige A, Seidel L, Noël A, et al. Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis. Br J Dermatol 2009;160:581-90.

87. Henno A, Blacher S, Lambert CA, Deroanne C, Noël A, Lapierre C, et al. Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis. J Dermatol Sci 2010;57:162-9.

88. Saban MR, Sferra TJ, Davis CA, Simpson C, Allen A, Maier J, et al. Neuropilin-VEGF signaling pathway acts as a key modulator of vascular, lymphatic, and inflammatory cell responses of the bladder to intravesical BCG treatment. Am J Physiol Renal Physiol 2010;299:F1245-56.